Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Background: Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease for which diagnosis and management remain challenging. Defining the circulating proteome in IPF may identify targets for biomarker development. We sought to quantify the circulating proteome in IPF, determine differential protein expression between subjects with IPF and controls, and examine relationships between protein expression and markers of disease severity. Methods: This study involved 300 patients with IPF from the IPF-PRO Registry and 100 participants without known lung disease. Plasma collected at enrolment was analysed using aptamer-based proteomics (1305 proteins). Linear regression was used to determine differential protein expression between participants with IPF and controls and associations between protein expression and disease severity measures (percent predicted values for forced vital capacity [FVC] and diffusion capacity of the lung for carbon monoxide [DLco]; composite physiologic index [CPI]). Multivariable models were fit to select proteins that best distinguished IPF from controls. Results: Five hundred fifty one proteins had significantly different levels between IPF and controls, of which 47 showed a |log 2(fold-change)| > 0.585 (i.e. > 1.5-fold difference). Among the proteins with the greatest difference in levels in patients with IPF versus controls were the glycoproteins thrombospondin 1 and von Willebrand factor and immune-related proteins C-C motif chemokine ligand 17 and bactericidal permeability-increasing protein. Multivariable classification modelling identified nine proteins that, when considered together, distinguished IPF versus control status with high accuracy (area under receiver operating curve = 0.99). Among participants with IPF, 14 proteins were significantly associated with FVC % predicted, 23 with DLco % predicted, 14 with CPI. Four proteins (roundabout homolog-2, spondin-1, polymeric immunoglobulin receptor, intercellular adhesion molecule 5) demonstrated the expected relationship across all three disease severity measures. When considered in pathways analyses, proteins associated with the presence or severity of IPF were enriched in pathways involved in platelet and haemostatic responses, vascular or platelet derived growth factor signalling, immune activation, and extracellular matrix organisation. Conclusions: Patients with IPF have a distinct circulating proteome and can be distinguished using a nine-protein profile. Several proteins strongly associate with disease severity. The proteins identified may represent biomarker candidates and implicate pathways for further investigation. Trial registration: ClinicalTrials.gov (NCT01915511).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Enrichr: a comprehensive gene set enrichment analysis web server 2016 update
Kuleshov, M. V., Jones, M. R., Rouillard, A. D., Fernandez, N. F., Duan, Q., Wang, Z., Koplev, S., Jenkins, S. L., Jagodnik, K. M., Lachmann, A., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw377 · Cited by 10,799
Kuhn, M., & Johnson, K. (2013) · doi:10.1007/978-1-4614-6849-3 · Cited by 6,788
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Self-citationDiagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Raghu, G., Remy-Jardin, M., Myers, J. L., Richeldi, L., Ryerson, C. J., Lederer, D. J., Behr, J., Cottin, V., Danoff, S. K., Morell, F., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201807-1255st · Cited by 4,103
Self-citationA phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper
Lynch, D. A., Sverzellati, N., Travis, W. D., Brown, K. K., Colby, T. V., Galvin, J. R., Goldin, J. G., Hansell, D. M., Inoue, Y., Johkoh, T., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30433-2 · Cited by 1,030
Wells, A. U., Desai, S. R., Rubens, M. B., Goh, N. S. L., Cramer, D., Nicholson, A. G., Colby, T. V., du Bois, R. M., & Hansell, D. M. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2111053 · Cited by 686
Jenkins, R. G., Simpson, J. K., Saini, G., Bentley, J. H., Russell, A.-M., Braybrooke, R., Molyneaux, P. L., McKeever, T. M., Wells, A. U., Flynn, A., et al. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00048-x · Cited by 314
Maher, T. M., Oballa, E., Simpson, J. K., Porte, J., Habgood, A., Fahy, W. A., Flynn, A., Molyneaux, P. L., Braybrooke, R., Divyateja, H., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30430-7 · Cited by 271
O'Brien, E. C., Durheim, M. T., Gamerman, V., Garfinkel, S., Anstrom, K. J., Palmer, S. M., & Conoscenti, C. S. (2016) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2015-000108 · Cited by 75
Self-citation
Cited by
Raghu, G., Remy-Jardin, M., Richeldi, L., Thomson, C. C., Inoue, Y., Johkoh, T., Kreuter, M., Lynch, D. A., Maher, T. M., Martinez, F. J., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202202-0399st · Cited by 2,957
Idiopathic pulmonary fibrosis: Current and future treatment
Glass, D. S., Grossfeld, D., Renna, H. A., Agarwala, P., Spiegler, P., DeLeon, J., & Reiss, A. B. (2022) · The Clinical Respiratory Journal · doi:10.1111/crj.13466 · Cited by 314
Inoue, Y., Kaner, R. J., Guiot, J., Maher, T. M., Tomassetti, S., Moiseev, S., Kuwana, M., & Brown, K. K. (2020) · Chest · doi:10.1016/j.chest.2020.03.037 · Cited by 133
Molecular programs of fibrotic change in aging human lung
Lee, S., Islam, M. N., Boostanpour, K., Aran, D., Jin, G., Christenson, S., Matthay, M. A., Eckalbar, W. L., DePianto, D. J., Arron, J. R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26603-2 · Cited by 78
Todd, J. L., Neely, M. L., Overton, R., Mulder, H., Roman, J., Lasky, J. A., de Andrade, J. A., Gulati, M., Huang, H., Leonard, T. B., et al. (2022) · Lung · doi:10.1007/s00408-021-00505-y · Cited by 14
“Patients with IPF have been shown to have a unique peripheral blood proteome [3, 4].”
BackgroundResultSelf-citation
Metadata
- Authors
- on behalf of the IPF-PRO Registry investigators, Todd, J. L., Neely, M. L., Overton, R., Durham, K., Gulati, M., Huang, H., Roman, J., Newby, L. K., Flaherty, K. R., Vinisko, R., Liu, Y., Roy, J., Schmid, R., Strobel, B., Hesslinger, C., Leonard, T. B., Noth, I., Belperio, J. A., & Palmer, S. M.
- Venue
- Respiratory Research
- Published
- 2019-10-22
- Volume
- 20
- Issue
- 1
- Pages
- 227-227
- ISSN
- 1465-9921 (ISSN-L)
- 1465-993X
- OpenAlex
- W2981363111
- Cited by
- 93
- References
- 11
- FWCI
- 6.59
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry. https://app.cochat.ai/papers/10.1186/s12931-019-1190-z
- The paper
- on behalf of the IPF-PRO Registry investigators, Todd, J. L., Neely, M. L., Overton, R., Durham, K., Gulati, M., Huang, H., Roman, J., Newby, L. K., Flaherty, K. R., Vinisko, R., Liu, Y., Roy, J., Schmid, R., Strobel, B., Hesslinger, C., Leonard, T. B., Noth, I., Belperio, J. A., & Palmer, S. M. (2019). Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry. Respiratory Research. https://doi.org/10.1186/s12931-019-1190-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.